Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Immunotherapy (eg interferon α) in combination with tyrosine kinase inhibitors is currently in clinical trials for treatment of chronic myeloid leukemia (CML). Cancer patients commonly have problems with so called immune escape mechanisms that may hamper immunotherapy. Hence, to study the function o...

Descripción completa

Detalles Bibliográficos
Autores principales: Christiansson, Lisa, Söderlund, Stina, Svensson, Emma, Mustjoki, Satu, Bengtsson, Mats, Simonsson, Bengt, Olsson-Strömberg, Ulla, Loskog, Angelica S. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561335/
https://www.ncbi.nlm.nih.gov/pubmed/23383287
http://dx.doi.org/10.1371/journal.pone.0055818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561335/
https://www.ncbi.nlm.nih.gov/pubmed/23383287
http://dx.doi.org/10.1371/journal.pone.0055818

Ejemplares similares